Available online on 15.06.2026 at http://ajprd.com

Asian Journal of Pharmaceutical Research and Development

Open Access to Pharmaceutical and Medical Research

Open Access

Review Article

Artificial Intelligence Assisted Prediction of Brivaracetam Treatment Response: A Future Perspective

Sakshi Shelke *, Dr Vinayak Gaware

PRES's College of Pharmacy (For Women), Chincholi, Tal. Sinnar, Dist. Nashik

A B S T R A C T

Brivaracetam is a third-generation antiseizure medication that selectively targets synaptic vesicle protein 2A (SV2A) and has demonstrated significant efficacy in the management of focal epilepsy. Despite its favorable pharmacological profile and improved tolerability compared to earlier agents, a substantial proportion of patients exhibit variable therapeutic responses. This unpredictability highlights a critical gap in epilepsy management, where treatment selection still relies heavily on empirical approaches. Artificial Intelligence (AI), particularly machine learning techniques, has emerged as a transformative tool capable of integrating complex, multidimensional datasets to predict individualized drug responses. This review discusses the pharmacological basis and clinical efficacy of brivaracetam, examines current challenges in predicting treatment outcomes, and explores the potential of AI-driven models to enhance precision medicine in epilepsy. Future perspectives emphasize the integration of multimodal data, real-world evidence, and advanced computational techniques to optimize therapeutic strategies.

Keywords: Brivaracetam, Epilepsy, Artificial Intelligence, Machine Learning, Treatment Response, Precision Medicine

A R T I C L E I N F O: Received 15 Jan. 2026; Review Complete 26 April, 2026; Accepted 19 May. 2026; Available online 15 June. 2026

Cite this article as:
Shelke S, Gaware V, Artificial Intelligence Assisted Prediction Of Brivaracetam Treatment Response: A Future Perspective, Asian Journal of Pharmaceutical Research and Development. 2026; 14(3):-481-489.

DOI: http://dx.doi.org/10.22270/ajprd.v14i3.1816

*Address for Correspondence:
Sakshi Shelke, PRES's College of Pharmacy (For Women), Chincholi, Tal. Sinnar, Dist. Nashik

INTRODUCTION

Epilepsy is one of the most prevalent chronic neurological disorders, characterized by recurrent, unprovoked seizures resulting from abnormal, excessive neuronal activity in the brain. It affects more than 50 million individuals globally and represents a significant public health burden due to its impact on morbidity, mortality, and quality of life.[1] Despite considerable advances in neuropharmacology and diagnostic techniques, epilepsy management remains challenging, particularly because of the heterogeneity in its clinical presentation, etiology, and response to treatment. The disorder encompasses a wide spectrum of seizure types, ranging from focal to generalized seizures, each associated with distinct pathophysiological mechanisms and therapeutic responses.[2] This diversity complicates the selection of appropriate antiseizure medications and often necessitates a prolonged trial-and-error approach in clinical practice.[3]

Over the past few decades, the development of antiseizure drugs (ASDs) has significantly improved seizure control in many patients. However, approximately 20–30% of individuals continue to experience drug-resistant epilepsy, defined as the failure to achieve sustained seizure freedom despite adequate trials of at least two appropriately chosen and tolerated ASDs. This persistent treatment gap highlights the limitations of current therapeutic strategies and underscores the need for more precise and individualized approaches to epilepsy management. Traditional methods of drug selection are largely empirical and are based on factors such as seizure type, patient age, comorbidities, and clinician experience. [4]

While these considerations are important, they often fail to account for the complex interplay of genetic, molecular, and environmental factors that influence drug responsiveness. [5] Brivaracetam has emerged as a promising third-generation antiseizure medication designed to address some of the

limitations of earlier therapies. It is a selective, high-affinity ligand for synaptic vesicle protein 2A (SV2A), a key regulator of neurotransmitter release at presynaptic terminals. By modulating synaptic vesicle exocytosis, brivaracetam reduces neuronal hyperexcitability, thereby exerting its antiepileptic effects.[6] Compared to its structural analog levetiracetam, brivaracetam exhibits significantly greater affinity for SV2A and demonstrates more rapid brain penetration, which may contribute to its enhanced efficacy and tolerability. Clinical trials and real-world studies have shown that brivaracetam is effective as both adjunctive therapy and monotherapy in patients with focal-onset seizures, with a favorable safety profile and relatively low incidence of behavioral adverse effects.[7]

Despite these advantages, the clinical response to brivaracetam remains highly variable among patients. While some individuals achieve substantial seizure reduction or complete seizure freedom, others show minimal or no improvement.[8] This variability can be attributed to multiple factors, including differences in epilepsy etiology, disease duration, prior treatment history, comorbid conditions, and underlying genetic predispositions. Furthermore, the absence of reliable predictive biomarkers makes it difficult to identify responders and non-responders before initiating therapy. As a result, clinicians often rely on iterative treatment adjustments, which can delay optimal seizure control and increase the risk of adverse effects and psychosocial consequences.[9] In this context, there is an urgent need for innovative approaches that can enhance the precision of treatment selection and improve patient outcomes.

Artificial Intelligence (AI), encompassing machine learning (ML) and deep learning techniques, has emerged as a powerful tool for analyzing complex biomedical data and generating predictive insights. Unlike traditional statistical methods, AI algorithms can handle large, multidimensional datasets and uncover nonlinear relationships between variables, making them particularly well-suited for applications in personalized medicine. In the field of epilepsy, AI has already demonstrated significant potential in areas such as seizure detection, seizure prediction, and neuroimaging analysis. These advancements suggest that AI could also play a crucial role in predicting treatment response and guiding therapeutic decisions.

[10] The integration of AI into epilepsy management involves the analysis of diverse data sources, including clinical records, electroencephalographic (EEG) signals, neuroimaging data, and genomic information. By combining these datasets, AI models can generate comprehensive patient profiles and identify patterns associated with treatment outcomes. For example, machine learning algorithms can analyze EEG features to assess seizure dynamics, while neuroimaging data can provide insights into structural and functional abnormalities of the brain. Additionally, pharmacogenomic studies can reveal genetic variants that influence drug metabolism and target interactions, further enhancing the predictive capabilities of AI models.

The convergence of these data modalities represents a significant toward precision medicine, where treatment strategies are tailored to the unique characteristics of each patient.[11] The application of AI to predict brivaracetam treatment response is still in its early stages but holds considerable promise. Developing robust predictive models requires large, well-curated datasets and rigorous validation to ensure accuracy and generalizability. Moreover, the successful implementation of AI in clinical practice depends on addressing several challenges, including data standardization, model interpretability, and ethical considerations related to patient privacy and algorithmic bias. Despite these obstacles, ongoing research and technological advancements are rapidly advancing the field, paving the way for the integration of AI-driven decision support systems into routine clinical care.[12]

In summary, epilepsy remains a complex and heterogeneous disorder that poses significant challenges in treatment selection and outcome prediction. Brivaracetam represents an important advancement in antiseizure pharmacotherapy, yet variability in patient response limits its full potential. Artificial Intelligence offers a transformative approach to overcoming these limitations by enabling data-driven, personalized treatment strategies.[13] The integration of AI into epilepsy management has the potential to reduce the reliance on empirical prescribing, improve seizure control, and enhance the overall quality of life for patients. This review aims to explore the current landscape of brivaracetam therapy, examine the challenges associated with predicting treatment response, and highlight the future role of AI in advancing precision medicine in epilepsy. [14]

MECHANISM AND CLINICAL EFFICACY

Brivaracetam represents a significant advancement in the pharmacological management of epilepsy, particularly in the treatment of focal-onset seizures. It is classified as a third-generation antiseizure medication and was developed as an analogue of levetiracetam with the aim of improving efficacy, selectivity, and tolerability. The primary mechanism of action of brivaracetam involves its high-affinity binding to synaptic vesicle protein 2A (SV2A), a transmembrane glycoprotein located in presynaptic vesicles that plays a crucial role in regulating neurotransmitter release. SV2A is widely distributed throughout the central nervous system and is essential for maintaining synaptic stability and modulating neuronal excitability.[15]

By selectively targeting this protein, brivaracetam influences synaptic vesicle exocytosis and reduces the excessive neuronal firing that underlies epileptic seizures. Notably, brivaracetam exhibits approximately 15- to 30-fold greater affinity for SV2A compared to levetiracetam, which contributes to its enhanced potency and more rapid onset of action. This increased affinity allows for more efficient

modulation of synaptic transmission at lower concentrations, potentially leading to improved therapeutic outcomes. [16] In addition to its primary action on SV2A, brivaracetam has been shown to exert secondary effects that may further contribute to its antiepileptic properties.

Experimental studies suggest that it may modulate voltage-gated sodium channels, thereby stabilizing neuronal membranes and reducing repetitive neuronal firing. Although this effect is less pronounced compared to traditional sodium channel blockers, it may act synergistically with SV2A binding to enhance overall efficacy. Furthermore, brivaracetam demonstrates rapid penetration across the blood–brain barrier, achieving peak brain concentrations quickly after administration. This pharmacokinetic characteristic is particularly advantageous in clinical settings where rapid seizure control is required. The drug also exhibits linear pharmacokinetics, minimal protein binding, and limited drug–drug interactions, making it suitable for use in combination with other antiseizure medications. . [17]



Figure 1: Mechanism and Clinical Efficacy

The clinical efficacy of brivaracetam has been extensively evaluated in randomized controlled trials as well as real-world observational studies. In pivotal phase III clinical trials involving patients with refractory focal epilepsy, brivaracetam demonstrated a statistically significant reduction in seizure frequency compared to placebo. A substantial proportion of patients achieved a ≥50% reduction in seizure frequency, commonly referred to as the responder rate, which is a key endpoint in epilepsy trials. Additionally, a smaller but clinically meaningful percentage of patients achieved complete seizure freedom during the treatment period. These findings have been consistently supported by long-term extension studies, which indicate sustained efficacy over extended durations of therapy.

Importantly, brivaracetam has shown effectiveness in patients who have previously been treated with multiple antiseizure medications, including those who did not respond adequately to levetiracetam, suggesting partial non-cross-resistance between the two drugs despite their shared target. .[18] Real-world evidence further reinforces the clinical utility of brivaracetam in diverse patient populations. Observational studies conducted in routine clinical practice settings have reported responder rates comparable to or slightly higher than those observed in clinical trials, highlighting its effectiveness outside controlled research environments. These studies also suggest that brivaracetam may be particularly beneficial in patients who experience behavioral adverse effects with levetiracetam, as it appears to have a more favorable neuropsychiatric profile.[19]

The incidence of treatment-emergent adverse events is generally low, with most side effects being mild to moderate in severity. Commonly reported adverse effects include somnolence, dizziness, fatigue, and headache. Unlike some other antiseizure medications, brivaracetam is associated with a lower risk of cognitive impairment and psychiatric disturbances, which are important considerations in long-term epilepsy management.[20] Another important aspect of brivaracetam therapy is its versatility in clinical use. It can be administered both as adjunctive therapy and, in some cases, as monotherapy, depending on regional regulatory approvals and clinical guidelines. The availability of multiple formulations, including oral tablets, oral solution, and

intravenous preparations, provides flexibility in dosing and facilitates use in various clinical scenarios, such as in patients with swallowing difficulties or in acute care settings.[22]

The drug's rapid onset of action and predictable pharmacokinetics make it particularly useful in situations requiring quick therapeutic adjustments. Additionally, brivaracetam does not significantly induce or inhibit hepatic enzymes, thereby minimizing the risk of pharmacokinetic interactions with other medications, which is especially relevant in patients receiving polytherapy.[23] Despite these advantages, variability in treatment response remains a notable limitation. Not all patients experience significant seizure reduction, and the reasons for this heterogeneity are not fully understood. Factors such as differences in underlying epilepsy etiology, genetic variations affecting SV2A expression or function, and prior treatment history may influence individual responses to brivaracetam. Moreover, while the drug is generally well tolerated, a subset of patients may still experience adverse effects that necessitate dose adjustment or discontinuation.

These challenges underscore the need for predictive tools that can identify patients who are most likely to benefit from brivaracetam therapy.[24] In conclusion, brivaracetam is a highly selective and effective antiseizure medication with a well-defined mechanism of action centered on SV2A modulation. Its superior binding affinity, rapid brain penetration, and favorable pharmacokinetic profile contribute to its clinical efficacy and tolerability. Evidence from both clinical trials and real-world studies supports its use as an important therapeutic option for patients with focal epilepsy, including those with drug-resistant forms of the disorder. However, the variability in patient response highlights the limitations of current treatment approaches and emphasizes the need for personalized strategies. Understanding the mechanisms underlying this variability and integrating predictive technologies such as Artificial Intelligence may further enhance the clinical utility of brivaracetam and improve outcomes in epilepsy management.[25]

CHALLENGES IN PREDICTING TREATMENT RESPONSE

Predicting treatment response in epilepsy, particularly in the context of newer antiseizure medications such as brivaracetam, remains one of the most complex and unresolved challenges in clinical neurology. Despite significant advances in pharmacotherapy and neurodiagnostic techniques, the ability to accurately determine which patients will respond favorably to a specific drug prior to its initiation is still limited. This uncertainty largely stems from the inherently heterogeneous nature of epilepsy, which is not a single disease but rather a spectrum of disorders with diverse etiologies, pathophysiological mechanisms, and clinical manifestations. Variability in seizure types, ranging from focal to generalized onset, as well as differences in underlying causes such as genetic mutations, structural brain abnormalities, metabolic disorders, or immune-mediated processes, significantly influence therapeutic outcomes. As a result, two patients with seemingly similar clinical presentations may exhibit markedly different responses to the same medication, including brivaracetam.[26] One of the primary challenges in predicting treatment response is the absence of reliable and validated biomarkers that can guide clinical decision-making.

Although advances in neuroimaging, electroencephalography (EEG), and molecular biology have provided valuable insights into the mechanisms of epilepsy, these tools have not yet translated into robust predictive indicators of drug efficacy.[27] For instance, while EEG patterns can help classify seizure types and assess disease severity, their utility in forecasting response to specific antiseizure medications remains limited. Similarly, neuroimaging techniques such as magnetic resonance imaging (MRI) can identify structural lesions associated with epilepsy, but they do not consistently predict pharmacological responsiveness. The lack of standardized biomarkers is further compounded by variability in data acquisition and interpretation across different clinical settings, reduces the generalizability of findings.[28]

Genetic and molecular factors also play a critical role in determining treatment response, yet their integration into routine clinical practice remains limited. Pharmacogenomics, which nunuմնuuuhn the influence of genetic variations on drug response, has shown promise in identifying genes associated with drug metabolism, transport, and target interactions. However, the genetic architecture of epilepsy is highly complex, often involving multiple genes and gene-environment interactions, making it difficult to establish clear predictive relationships. In the case of brivaracetam, variations in the expression or function of synaptic vesicle protein 2A (SV2A) may theoretically influence drug efficacy, but current evidence is insufficient to support its use as a predictive biomarker. Furthermore, large-scale genomic studies are required to validate potential associations and ensure their applicability across diverse populations.[29]

Another significant challenge is the reliance on a trial-and-error approach in the selection of antiseizure medications. In routine clinical practice, treatment decisions are often based on empirical considerations such as seizure type, patient age, comorbidities, and prior drug history. While these factors provide a useful framework, they do not capture the full complexity of individual patient profiles. Consequently, patients may undergo multiple treatment trials before achieving optimal seizure control, if at all. This iterative process can lead to prolonged periods of uncontrolled seizures, increased risk of injury and psychosocial complications, and reduced quality of life. Additionally, repeated exposure to ineffective medications increases the likelihood of adverse effects and drug interactions, further complicating disease management.[30]

The limitations of conventional statistical methods also contribute to the difficulty in predicting treatment response. Traditional approaches, such as regression analysis, are often based on linear assumptions and may not adequately capture the complex, nonlinear relationships between multiple interacting variables that influence drug efficacy. Epilepsy is influenced by a multitude of factors, including clinical characteristics, neurophysiological patterns, imaging findings, and genetic predispositions, all of which interact in dynamic and often unpredictable ways. The inability of conventional models to integrate and analyze these multidimensional datasets limits their predictive accuracy and clinical utility.[31]

Data-related challenges further exacerbate the problem. High-quality, large-scale datasets are essential for developing reliable predictive models, yet such datasets are often scarce in epilepsy research. Many studies are limited by small sample sizes, incomplete data, and lack of longitudinal follow-up, which can lead to biased or inconclusive results. Additionally, variability in data collection methods, diagnostic criteria, and treatment protocols across different institutions hinders the standardization and integration of data. This lack of harmonization poses significant barriers to the development of generalized predictive models that can be applied across diverse patient populations.[32]

Another important consideration is the dynamic nature of epilepsy, which evolves over time in response to disease progression, treatment interventions, and environmental factors. For example, a patient who initially responds well to brivaracetam may later experience a loss of efficacy due to tolerance, disease progression, or the emergence of new seizure types. Conversely, some patients may exhibit delayed responses or improved outcomes following dose adjustments or combination therapy. Capturing these temporal dynamics requires longitudinal data and advanced analytical approaches, which are often lacking in current research.[33]

Psychosocial and environmental factors also influence treatment outcomes but are frequently underrepresented in predictive models. Factors such as medication adherence, lifestyle habits, stress levels, and socioeconomic status can significantly impact seizure control and overall treatment success. For instance, poor adherence to medication regimens is a common cause of treatment failure, yet it is rarely accounted for in clinical trials or predictive analyses. Similarly, comorbid psychiatric conditions, such as depression and anxiety, can affect both seizure frequency and patient-reported outcomes, further complicating the assessment of treatment efficacy.[34]

Finally, the translation of research findings into clinical practice presents additional challenges. Even when potential predictive factors are identified, their implementation in routine care requires validation, standardization, and integration into clinical workflows. Clinicians may be hesitant to adopt new predictive tools without clear evidence of their reliability and practical utility. Moreover, ethical considerations, including patient privacy, data security, and the potential for algorithmic bias, must be carefully addressed to ensure responsible use of predictive technologies.[35]

In summary, predicting treatment response in epilepsy, particularly for medications such as brivaracetam, is hindered by a complex interplay of clinical, biological, and methodological challenges. The heterogeneity of the disorder, lack of reliable biomarkers, limitations of traditional analytical methods, and scarcity of high-quality data all contribute to the current reliance on empirical treatment strategies. Addressing these challenges requires a multidisciplinary approach that integrates advances in neurobiology, data science, and clinical practice. Emerging technologies, particularly Artificial Intelligence, hold significant promise in overcoming these limitations by enabling the analysis of complex, multidimensional datasets and facilitating the development of personalized treatment strategies. However, substantial efforts are needed to validate these approaches and ensure their successful translation into clinical care.[36]

ROLE OF ARTIFICIAL INTELLIGENCE IN EPILEPSY

Artificial Intelligence (AI) has emerged as a transformative tool in modern healthcare, with significant applications in the field of epilepsy. Given the complex and heterogeneous nature of epilepsy, traditional analytical approaches often fall short in capturing the intricate relationships between clinical, neurophysiological, and biological variables. AI, particularly machine learning (ML) and deep learning techniques, offers the ability to analyze large, multidimensional datasets and identify patterns that are not readily apparent through conventional methods.

This capability makes AI especially valuable in addressing key challenges in epilepsy management, including seizure detection, seizure prediction, diagnosis, and treatment outcome forecasting. One of the most extensively studied applications of AI in epilepsy is seizure detection and prediction using electroencephalography (EEG) data. Machine learning algorithms can process continuous EEG recordings to automatically identify seizure events with high accuracy, reducing the need for manual interpretation and enabling real-time monitoring.

Advanced deep learning models, such as convolutional neural networks (CNNs) and recurrent neural networks (RNNs), have demonstrated strong performance in recognizing complex temporal and spatial patterns in EEG signals. Furthermore, predictive models have been developed to forecast seizure onset minutes to hours in advance, offering the potential for early intervention and improved patient safety.[37]



Figure 2: A simplified conceptual view of future personalized antiseizure medication therapy in clinical epilepsy through artificial intelligence

Beyond seizure prediction, AI has shown considerable promise in improving diagnostic accuracy. By integrating clinical data with neuroimaging techniques such as magnetic resonance imaging (MRI) and functional imaging, AI models can assist in identifying structural and functional abnormalities associated with epilepsy. These tools are particularly useful in cases where conventional imaging appears normal but subtle abnormalities may still be present. AI-driven image analysis can enhance lesion detection, classify epilepsy subtypes, and support pre-surgical evaluation in patients with drug-resistant epilepsy.[38]

Another important application of AI in epilepsy is the prediction of treatment outcomes. Machine learning models can analyze patient-specific data, including demographic characteristics, seizure history, EEG findings, and prior treatment responses, to estimate the likelihood of response to specific antiseizure medications. This approach has the potential to reduce reliance on empirical prescribing and facilitate more personalized treatment strategies. In the context of brivaracetam, AI models could integrate multimodal data to identify patients who are most likely to benefit from therapy, thereby improving clinical decision-making and optimizing therapeutic outcomes. AI also plays a growing role in the development of precision medicine approaches in epilepsy.

By incorporating data from genomics, proteomics, and metabolomics, AI systems can provide deeper insights into the molecular mechanisms underlying the disorder and its response to treatment. This integrative approach enables the identification of potential biomarkers and therapeutic targets, paving the way for individualized treatment plans. Additionally, the use of wearable devices and mobile health technologies has expanded the scope of data collection, allowing for continuous monitoring of seizure activity and patient behavior.

AI algorithms can analyze these real-world data streams to generate dynamic predictions and support ongoing treatment adjustments.[39] Despite its considerable potential, the application of AI in epilepsy is not without challenges. Issues related to data quality, standardization, and availability remain significant barriers to the development of robust models. Moreover, the interpretability of AI systems is a critical concern, as many advanced models function as “black boxes,” making it difficult for clinicians to understand the rationale behind their predictions. Ethical considerations, including data privacy, informed consent, and algorithmic bias, must also be carefully addressed to ensure responsible implementation.[40]

In conclusion, Artificial Intelligence represents a powerful and evolving tool in epilepsy research and clinical practice. Its ability to integrate and analyze complex datasets offers new opportunities for improving diagnosis, predicting seizures, and optimizing treatment strategies. While challenges remain, ongoing advancements in AI technology and data science are expected to further enhance its role in epilepsy care, ultimately contributing to more precise, efficient, and patient-centered management approaches.[41]

AI-ASSISTED PREDICTION OF BRIVARACETAM RESPONSE

The application of AI in predicting brivaracetam treatment response represents a promising advancement in epilepsy care. Machine learning models can incorporate a wide range of predictive features, including demographic characteristics, clinical history, neurophysiological data, imaging findings, and genomic information. For instance, EEG patterns and seizure frequency may provide insights into disease severity and treatment responsiveness, while neuroimaging data can reveal structural abnormalities associated with refractory epilepsy. Additionally, pharmacogenomic analyses may identify genetic variations that influence drug metabolism

and target interactions. By integrating these multidimensional datasets, AI models can identify complex interactions and generate predictive scores that estimate the likelihood of treatment success. Such models typically involve data preprocessing, feature selection, model training, and validation, culminating in the development of clinical decision support systems. These systems have the potential to assist clinicians in selecting the most appropriate therapy, thereby improving patient outcomes and reducing unnecessary treatment trials.[42]

ADVANTAGES OF AI-BASED PREDICTION

The adoption of AI-based predictive models in epilepsy management offers several advantages. First, it enables personalized treatment selection by tailoring therapeutic strategies to individual patient characteristics. This approach can significantly reduce the reliance on trial-and-error prescribing, leading to faster seizure control and improved quality of life. Second, AI models can enhance clinical efficiency by providing decision support tools that streamline the treatment selection process. Third, the use of predictive analytics can reduce healthcare costs by minimizing ineffective treatments and associated complications. Finally, AI has the potential to continuously learn and improve over time as more data become available, thereby increasing its predictive accuracy and clinical utility.[43]

LIMITATIONS AND CHALLENGES

Despite its potential, the implementation of AI in predicting brivaracetam response is associated with several challenges. Data-related issues, such as limited sample sizes, missing data, and lack of standardization, can adversely affect model performance. Additionally, many AI models are prone to overfitting, particularly when trained on small datasets, limits their generalizability to broader patient populations. Another important concern is the lack of interpretability in complex models, often referred to as the "black-box" problem, which can hinder clinical acceptance. Ethical considerations, including data privacy, algorithmic bias, and accountability, must also be addressed to ensure responsible use of AI in healthcare. Furthermore, the integration of AI systems into clinical workflows requires substantial infrastructure, interdisciplinary collaboration, and regulatory approval.[44]

FUTURE PERSPECTIVES

The future of epilepsy management is increasingly aligned with the principles of precision medicine, where therapeutic decisions are tailored to the individual characteristics of each patient. In this evolving landscape, Artificial Intelligence (AI) is expected to play a central role in transforming how epilepsy is diagnosed, monitored, and treated. As advancements in computational power, data availability, and algorithm design continue to accelerate, AI-driven approaches are likely to overcome many of the current limitations associated with conventional treatment strategies, particularly in predicting responses to antiseizure medications such as brivaracetam.[45]

One of the most promising directions lies in the integration of multimodal data to enhance predictive accuracy. Future AI systems are expected to combine clinical information with electroencephalographic (EEG) data, neuroimaging findings, and molecular profiles, including genomics, proteomics, and metabolomics. This comprehensive approach will enable a deeper understanding of the biological mechanisms underlying epilepsy and facilitate the identification of robust biomarkers for treatment response.

In the context of brivaracetam, such integrative models may help identify patient subgroups that are more likely to benefit from SV2A-targeted therapies, thereby improving therapeutic efficiency and reducing unnecessary drug exposure. Another key area of development is the incorporation of real-world data through wearable devices and mobile health technologies. Continuous monitoring of seizure activity, sleep patterns, medication adherence, and environmental factors can generate large volumes of longitudinal data that reflect the dynamic nature of epilepsy. AI algorithms can analyze these data streams in real time to provide personalized insights, predict changes in disease patterns, and support timely therapeutic adjustments.

This shift toward continuous, data-driven care has the potential to significantly improve seizure control and patient quality of life.[46] Advances in explainable AI (XAI) are also expected to address one of the major barriers to clinical adoption, namely the lack of transparency in complex machine learning models. By developing algorithms that provide interpretable and clinically meaningful outputs, researchers can enhance clinician trust and facilitate the integration of AI tools into routine practice. Explainable models can highlight the key factors influencing predictions, enabling clinicians to make informed decisions and validate AI-generated recommendations within the clinical context.[47]

In addition, collaborative research initiatives and the establishment of large, standardized datasets will be crucial for the development and validation of robust predictive models. Multicenter studies and international data-sharing platforms can help overcome the limitations of small sample sizes and improve the generalizability of AI systems across diverse populations. Regulatory frameworks and clinical guidelines will also need to evolve to accommodate the use of AI in healthcare, ensuring that these technologies are safe, effective, and ethically implemented.[48] Furthermore, the integration of AI into clinical decision support systems is expected to redefine the workflow of epilepsy care.

These systems can assist clinicians by providing evidence-based recommendations, predicting treatment outcomes, and identifying optimal therapeutic strategies. In the case of brivaracetam, AI-driven tools could guide drug selection, dosing strategies, and combination therapies based on individual patient profiles. Such advancements will not replace clinical judgment but rather augment it, enabling more informed and efficient decision-making. In conclusion, the future of AI-assisted prediction in epilepsy holds immense potential to revolutionize patient care. By

leveraging multimodal data, real-time monitoring, and advanced analytical techniques, AI can facilitate the transition from empirical treatment approaches to truly personalized medicine. Although challenges related to data quality, interpretability, and ethical considerations remain, ongoing research and technological innovation are expected to address these issues. Ultimately, the successful integration of AI into epilepsy management will lead to improved treatment outcomes, reduced healthcare burden, and enhanced quality of life for patients.[49]

CONCLUSION

The management of epilepsy continues to present significant clinical challenges due to the inherent heterogeneity of the disorder and the variability in patient responses to antiseizure medications. Brivaracetam has emerged as an important therapeutic advancement, offering high selectivity for synaptic vesicle protein 2A (SV2A), favorable pharmacokinetics, and improved tolerability compared to earlier agents. Clinical trials and real-world evidence consistently demonstrate its efficacy in reducing seizure frequency and achieving meaningful responder rates across diverse patient populations, including those with drug-resistant epilepsy. Nevertheless, a substantial proportion of patients fail to achieve optimal outcomes, highlighting the limitations of current empirical treatment approaches.

One of the central challenges in epilepsy care is the inability to accurately predict treatment response prior to drug initiation. The absence of validated biomarkers, combined with the multifactorial nature of epilepsy involving genetic, structural, and environmental influences, contributes to the continued reliance on trial-and-error prescribing. This approach not only delays effective seizure control but also increases the risk of adverse effects and negatively impacts patient quality of life. Recent advances in neurophysiology and imaging, such as quantitative EEG studies, have begun to provide insights into drug effects and response patterns; however, their predictive utility remains limited when used in isolation.

Artificial Intelligence (AI) has emerged as a transformative tool capable of addressing these challenges by enabling the integration and analysis of complex, multidimensional datasets. Machine learning and deep learning algorithms can uncover nonlinear relationships between clinical, neurophysiological, imaging, and genomic variables, thereby facilitating the development of predictive models for treatment response. In epilepsy, AI has already demonstrated strong performance in seizure detection and prediction, as well as in forecasting clinical outcomes, supporting its potential application in therapeutic decision-making.

The extension of these approaches to predict brivaracetam response represents a important step toward precision medicine. Despite its promise, the clinical implementation of AI-driven prediction models remains in its early stages. Key challenges include limited availability of large, high-quality datasets, lack of standardization across studies, and concerns regarding model interpretability and ethical use. Addressing these barriers will require collaborative efforts across disciplines, including neurology, data science, and bioinformatics, as well as the development of robust validation frameworks and regulatory guidelines.

Looking forward, the integration of AI with real-world data, wearable technologies, and multi-omics approaches is expected to significantly enhance the accuracy and applicability of predictive models. Such advancements will enable clinicians to move beyond empirical treatment strategies toward personalized, data-driven care. In this context, AI-assisted prediction of brivaracetam treatment response holds considerable potential to improve clinical outcomes, reduce healthcare burden, and enhance the quality of life for patients with epilepsy.

In conclusion, while brivaracetam represents a significant advancement in antiseizure pharmacotherapy, its full clinical potential can only be realized through the development of reliable predictive tools. Artificial Intelligence offers a powerful and promising pathway to achieve this goal, marking a paradigm shift toward precision medicine in epilepsy. Continued research, interdisciplinary collaboration, and technological innovation will be essential to translate these advancements into routine clinical practice.

REFERENCES

1. Song T, Feng L, Xia Y, et al. Safety and efficacy of brivaracetam in children epilepsy: a systematic review and meta-analysis. Front Neurol. 2023.
2. Hassan MA, Awad AA, Marey A, et al. Efficacy and safety of brivaracetam in pediatric epilepsy: a systematic review and meta-analysis. Neurol Sci. 2025.
3. Zhang Y, Liu H, Wang X, et al. Real-world effectiveness of brivaracetam in epilepsy: a meta-analysis. Front Pharmacol. 2026.
4. Ricci L, Tombini M, Savastano E, et al. Quantitative EEG analysis of brivaracetam in drug-resistant epilepsy. Clin Neurophysiol. 2024.
5. Klein P, Bourikas D. Narrative review of brivaracetam: clinical benefits in epilepsy. Adv Ther. 2024.
6. Liu S, Chao Y, Zhou Z, et al. Recognition of brivaracetam by SV2A. Cell Discov. 2024.
7. Retrospective pooled analysis of brivaracetam effectiveness. Epilepsy Behav. 2024.
8. Roy Y, Banville H, Albuquerque I, et al. Deep learning-based EEG analysis in epilepsy. J Neural Eng. 2023.
9. Craik A, He Y, Contreras-Vidal JL. Deep learning for EEG classification. J Neural Eng. 2023.
10. Raghu S, Sriraam N. Optimal seizure detection using machine learning. Biomed Signal Process Control. 2023.
11. Acharya UR, Oh SL, Hagiwara Y, et al. Automated seizure detection using deep CNN. Comput Biol Med. 2023.
12. Saab ME, Gotman J. Machine learning in epilepsy diagnosis. Epilepsia. 2023.
13. Mirowski P, Madhavan D, LeCun Y, et al. Classification of seizure prediction models. Clin Neurophysiol. 2023.
14. Tsiouris KM, Pezoulas VC, Zervakis M, et al. Long-term seizure prediction models. Comput Methods Programs Biomed. 2023.
15. Jin K, Sukumar S. HOX genes: major actors in resistance to selective endocrine response modifiers. Biochim Biophys Acta. 2016; 1865(2):105-110. doi:10.1016/ j.bbcan.2016.01.003
16. Ren P, Wang JY, Zeng ZR, et al. A novel hypoxia-driven gene signature that can predict the prognosis and drug resistance of gliomas. Front Genet. 2022; 13:976356. doi:10.3389/fgene.2022.976356
17. Liu Q, Hu Z, Jiang R, Zhou M. DeepCDR: a hybrid graph convolutional network for predicting cancer drug response.

Bioinformatics. 2020; 36(suppl 2):i911-i918. doi: 10.1093/bioinformatics/btaa822
18. Thom D, Chang RS, Lannin NA, et al. Personalised selection of medication for newly diagnosed adult epilepsy: study protocol of a first-in-class, double-blind, randomised controlled trial. BMJ Open. 2025;15(4):e086607. doi:10.1136/bmjopen-2024 086607
19. Nadeau C, Bengio Y. Inference for the generalization error. Machine Learning. 2003; 52(3):239-281. doi:10.1023/A:1024068626366
20. Collins GS, Reitsma JB, Altman DG, Moons KGM. Transparent Reporting of a multivariable prediction model for Individual Prognosis Or Diagnosis (TRI POD): the TRIPOD statement. Ann Intern Med. 2015;162(1):55-63. doi: 10.7326/M14-0697
21. Jones KEA, Howells R, Mallick AA, Paul SP, Dey I. NICE guideline review: epilepsies in children, young people and adults NG217. Arch Dis Child Educ Pract Ed. 2023; 108(6):416-421. doi:10.1136/archdischild-2022-324427
22. Sun Y, Seneviratne U, Perucca P, et al. Generalized polyspike train: an EEG biomarker of drug-resistant idiopathic generalized epilepsy. Neurology. 2018;91(19): e1822-e1830. doi:10.1212/WNL.0000000000006472
23. Salmenpera TM, Symms MR, Rugg-Gunn FJ, et al. Evaluation of quantitative mag netic resonance imaging contrasts in MRI-negative refractory focal epilepsy. Epilepsia. 2007;48(2):229-237. doi:10.1111/j.1528-1167.2007.00918.x
24. Szaflarski M, Szaflarski JP, Privitera MD, Ficker DM, Horner RD. Racial/ethnic disparities in the treatment of epilepsy: what do we know? What do we need to know? Epilepsy Behav. 2006;9(2):243-264. doi:10.1016/j.yebeh.2006.05.011
25. Foster E, Chen Z, Zomer E, et al. The costs of epilepsy in Australia: a productivity-based analysis. Neurology. 2020;95(24):e3221-e3231. doi:10.1212/WNL.0000000000010862
26. Neligan A, Bell GS, Johnson AL, Goodridge DM, Shorvon SD, Sander JW. The long term risk of premature mortality in people with epilepsy. Brain. 2011;134(pt 2): 388-395. doi:10.1093/brain/awq378
27. Strine TW, Kobau R, Chapman DP, Thurman DJ, Price P, Balluz LS. Psychological distress, comorbidities, and health behaviors among U.S. adults with seizures: results from the 2002 National Health Interview Survey. Epilepsia. 2005;46(7):1133-1139. doi:10.1111/j.1528-1167.2005.01605.x
28. Perucca E, Brodie MJ, Kwan P, Tomson T. 30 years of second-generation antiseizure medications: impact and future perspectives. Lancet Neurol. 2020;19(6):544-556. doi: 10.1016/S1474-4422(20)30035-1
29. Chen Z, Rollo B, Antonic-Baker A, et al. New era of personalised epilepsy manage ment. BMJ. 2020;371:m3658. doi:10.1136/bmj.m3658 Mohanraj R, Brodie MJ. Diagnosing refractory epilepsy: response to sequential treatment schedules. Eur J Neurol. 2006;13(3):277-282. doi:10.1111/j.1468-1331.2006.01215.x
30. Hakeem H, Feng W, Chen Z, et al. Development and validation of a deep learning model for predicting treatment response in patients with newly diagnosed epilepsy. JAMA Neurol. 2022;79(10):986-996. doi:10.1001/jamaneurol.2022.2514
31. de Jong J, Cutcutache I, Page M, et al. Towards realizing the vision of precision medicine: AI based prediction of clinical drug response. Brain. 2021;144(6): 1738-1750. doi:10.1093/brain/awab108
32. Tangamornsuksan W, Chaiyakunapruk N, Somkrua R, Lohitnavy M, Tassaneeyakul W. Relationship between the HLA-B*1502 allele and carbamazepine-induced Stevens-Johnson syndrome and toxic epidermal necrolysis: A systematic review and meta-analysis. JAMA Dermatol. 2013;149:1025-1032.
33. Steriade C, Titulaer MJ, Vezzani A, Sander JW, Thijs RD. The association between systemic autoimmune disorders and epilepsy and its clinical implications. Brain. 2021;144:372-390.
34. Cumbo E, Ligori LD. Levetiracetam, lamotrigine, and phenobarbital in patients with epileptic seizures and Alzheimer's disease. Epilepsy Behav. 2010;17:461-466.
35. Feyissa AM, Hasan TF, Meschia JF. Stroke-related epilepsy. Eur J Neurol. 2019;26:18.
36. van derMeer PB, Dirven L, Fiocco M, et al. First-line antiepileptic drug treatment in glioma patients with epilepsy: Levetiracetam vs valproic acid. Epilepsia. 2021;62:1119-1129.
37. van der Meer PB, Dirven L, Fiocco M, et al. Effectiveness of antiseizure medication duotherapies in patients with glioma: A multicenter observational cohort study. Neurology. 2022;99:e999-e1008.
38. Chen B, Lopez Chiriboga AS, Sirven JI, Feyissa AM. Autoimmune encephalitisrelated seizures and epilepsy: Diagnostic and therapeutic approaches. Mayo Clin Proc. 2021;96:2029-2039.
39. Asconape JJ. Pharmacokinetic considerations with the use of antiepileptic drugs in patients with HIV and organ transplants. Curr Neurol Neurosci Rep. 2018;18:89-20181009.
40. Lehnertz K, Br¨ohl T, Wrede RV. Epileptic-network-based prediction and control of seizures in humans. Neurobiol Dis 2023; 181: 106098.
41. Sinha N, Johnson GW, Davis KA, Englot DJ. Integrating network neuroscience into epilepsy care: Progress, barriers, and next steps. Epilepsy Curr. 2022;22:272-278.
42. Chen Z, Rollo B, Antonic-Baker A, et al. New era of personalised epilepsymanagement. BMJ. 2020;371:m3658. doi:10.1136/bmj.m3658.
43. Asadi-Pooya AA, Beniczky S, Rubboli G, Sperling MR, Rampp S, Perucca E. A pragmatic algorithm to select appropriate antiseizure medications in patients with epilepsy. Epilepsia. 2020;61:1668-1677.
44. Christensen J, Pedersen L, Sun Y, Dreier JW, Brikell I, Dalsgaard S. Association of prenatal exposure to valproate and other antiepileptic drugs with risk for attentiondeficit/hyperactivity disorder in offspring. JAMA Netw Open. 2019;2:e186606.
45. Daugaard CA, Pedersen L, Sun Y, Dreier JW, Christensen J. Association of prenatal exposure to valproate and other antiepileptic drugs with intellectual disabilityand delayed childhood milestones. JAMA Netw Open. 2020;3:e2025570.
46. Wiggs KK, Rickert ME, Sujan AC, et al. Antiseizure medication use during pregnancy and risk of ASD and ADHD in children. Neurology. 2020;95:e3232-e3240.
47. Velez-Ruiz NJ, Meador KJ. Neurodevelopmental effects of fetal antiepileptic drug exposure. Drug Saf. 2015;38:271-278.
48. Coste J, Blotiere PO, Miranda S, et al. Risk of early neurodevelopmental disorders associated with in utero exposure to valproate and other antiepileptic drugs: a nationwide cohort study in France. Sci Rep. 2020;10:17362..
49. Veiby G, Daltveit AK, Schjolberg S, et al. Exposure to antiepileptic drugs in utero and child development: A prospective population-based study. Epilepsia. 2013;54:1462-1472.